A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Leukemia

• Publication date

  2013-04-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2013.102PMID 23558526
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

  2013cited by this paper
• JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms

  2012cited by this paper
• Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

  2012cited by this paper
• The role of mutations in epigenetic regulators in myeloid malignancies

  2012cited by this paper
• SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.

  2012cited by this paper
• JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

  2012cited by this paper
• More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance

  2011cited by this paper
• TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

  2011cited by this paper
• JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

  2011cited by this paper
• Do reactive oxygen species play a role in myeloid leukemias?

  2011cited by this paper
• New mutations and pathogenesis of myeloproliferative neoplasms.

  2011cited by this paper
• Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

  2011cited by this paper
• Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

  2010cited by this paper
• TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

  2010cited by this paper
• NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases

  2010cited by this paper
• ROS‐mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3−/− mice

  2010cited by this paper
• Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia

  2009cited by this paper
• JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

  2009cited by this paper
• VEGFR1-activity-independent metastasis formation

  2009cited by this paper
• Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes.

  2009cited by this paper
• JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

  2008cited by this paper
• Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.

  2008cited by this paper
• Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

  2008cited by this paper
• Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.

  2008cited by this paper
• consequences for the repair of DNA double strand breaks in chronic myeloid leukemia : α Up-regulation of WRN and DNA ligase III

  2008cited by this paper
• Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms

  2008cited by this paper
• Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.

  2008cited by this paper
• FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.

  2007cited by this paper
• A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche.

  2007cited by this paper
• JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

  2007cited by this paper
• Chromatin Structure Regulates Gene Conversion

  2007cited by this paper
• The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.

  2007cited by this paper
• Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.

  2007cited by this paper
• Cell signaling. H2O2, a necessary evil for cell signaling.

  2006cited by this paper
• Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition*

  2006cited by this paper
• JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

  2006cited by this paper
• Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

  2006cited by this paper
• BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

  2006cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells

  2004cited by this paper

• Targeting the JAK2V617F mutant hematopoietic microenvironment in myeloproliferative neoplasm

  2026cites this paper
• Cellular expression of PD-1, PD-L1 and CTLA-4 in patients with JAK2V617F mutated myeloproliferative disorders

  2025cites this paper
• Targeting mitochondrial dysfunction in myeloproliferative neoplasms: current strategies and future directions – a narrative review

  2025influential citation
• The Dual Role of Interferon Signaling in Myeloproliferative Neoplasms: Pathogenesis and Targeted Therapeutics

  2025cites this paper
• Metabolomic Profiling Reveals Distinct Signatures in Primary and Secondary Polycythemia

  2025cites this paper
• Atrial Fibrillation in Philadelphia Chromosome–negative Myeloproliferative Neoplasms: Thromboinflammatory Crosstalk with a Focus on the NLRP3 Inflammasome

  2025cites this paper
• Management of Myeloproliferative Neoplasms: An Integrative Approach

  2025cites this paper
• Reconsidering ‘primary myelofibrosis with increased haemoglobin’ within the myeloproliferative neoplasms biological continuum

  2025cites this paper
• Chronic Inflammation in Primary Myelofibrosis: In-Depth Insights Into Pathogenesis and Promising Anti-Inflammatory Therapeutic Strategies

  2025cites this paper
• Oxidant/Antioxidant Status in Patients with BCR-ABL1 Negative Myeloproliferative Neoplasms

  2024cites this paper
• Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms

  2024cites this paper
• The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms

  2024cites this paper
• Evaluation the Medicinal Potential of Phallus indusiatus as a Protein-Rich Source for Applications in Meat Analogs

  2024cites this paper
• The CHIP-clinic as the catalyst of preventive medicine

  2024cites this paper
• JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications

  2024cites this paper
• TLR2 Derangements Likely Play a Significant Role in the Inflammatory Response and Thrombosis in Patients with Ph(−) Classical Myeloproliferative Neoplasm

  2024cites this paper
• Polycythemia vera: past, present and future

  2024cites this paper
• JAK2V617F allele burden in polycythemia vera: burden of proof

  2023cites this paper
• Polyglobulie de Vaquez

  2023cites this paper
• Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms

  2023cites this paper
• Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?

  2023cites this paper
• Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia

  2023cites this paper
• Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia

  2023cites this paper
• Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms

  2023cites this paper
• Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia‐chromosome negative myeloproliferative neoplasms

  2023cites this paper
• Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms

  2023cites this paper
• Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature

  2023cites this paper
• Effect of hypoxia on HIF-1α and NOS3 expressions in CD34+ cells of JAK2V617F-positive myeloproliferative neoplasms.

  2023cites this paper
• Increased reactive oxygen species lead to overactivation of platelets in essential thrombocythemia.

  2023cites this paper
• Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model

  2023cites this paper
• Putative Role of Neutrophil Extracellular Trap Formation in Chronic Myeloproliferative Neoplasms

  2023cites this paper
• Interferon alpha‐2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms

  2023cites this paper
• Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer

  2022cites this paper
• Ruxolitinib Reduces Oxidative Stress in Patients With Primary Myelofibrosis: A Multicenter Study

  2022cites this paper
• Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality

  2022cites this paper
• Genetic basis and molecular profiling in myeloproliferative neoplasms

  2022cites this paper
• Ropeginterferon-alfa2b resolves angina pectoris and reduces JAK2V617F in a patient with clonal hematopoiesis of indeterminate potential: A case report

  2022cites this paper
• FoxO Transcription Factors: Applicability as a Novel Immune Cell Regulators and Therapeutic Targets in Oxidative Stress-Related Diseases

  2022cites this paper
• Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy

  2022cites this paper
• Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms

  2022cites this paper
• PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review

  2022cites this paper
• Advances in understanding the molecular basis of clonal hematopoiesis.

  2022cites this paper
• Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.

  2022cites this paper
• Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms

  2022cites this paper
• Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms

  2022cites this paper
• Inflammation Promotes Oxidative and Nitrosative Stress in Chronic Myelogenous Leukemia

  2022cites this paper
• JAK2 in Myeloproliferative Neoplasms: Still a Protagonist

  2022cites this paper
• Neutrophil Death in Myeloproliferative Neoplasms: Shedding More Light on Neutrophils as a Pathogenic Link to Chronic Inflammation

  2022influential citation
• The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis

  2022cites this paper
• Lessons from mouse models of MPN.

  2022cites this paper
• Physiological Signaling Functions of Reactive Oxygen Species in Stem Cells: From Flies to Man

  2021cites this paper
• Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives

  2021cites this paper
• New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms

  2021cites this paper
• MTAP-related increased erythroblast proliferation as a mechanism of polycythaemia vera

  2021cites this paper
• The JAK2 mutation.

  2021cites this paper
• New Markers of Disease Progression in Myelofibrosis

  2021cites this paper
• Primary Immune Thrombocytopenia and Essential Thrombocythemia: So Different and yet Somehow Similar—Cases Series and a Review of the Literature

  2021cites this paper
• Reactive Oxygen Species in Acute Lymphoblastic Leukaemia: Reducing Radicals to Refine Responses

  2021cites this paper
• NK Cells in Myeloproliferative Neoplasms (MPN)

  2021cites this paper
• Data‐driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis

  2021cites this paper
• Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells

  2021cites this paper
• High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells

  2021cites this paper
• A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells.

  2021cites this paper
• Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera

  2021cites this paper
• Molecular basis of essential thrombocythaemia in humans and dogs – a review

  2021cites this paper
• Polycythemia Vera (PV): Update on Emerging Treatment Options

  2021cites this paper
• Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies

  2021cites this paper
• Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study

  2021cites this paper
• Immunotherapy in Myeloproliferative Diseases

  2020cites this paper
• Deletion of miR-451 curbs JAK2(V617F)-induced erythrocytosis in polycythemia vera by oxidative stress-mediated erythroblast apoptosis and hemolysis

  2020cites this paper
• Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis

  2020cites this paper
• Prevalence of JAK2 V617F Mutation in Iranian Patients with Myeloproliferative Neoplasms

  2020cites this paper
• Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm

  2020cites this paper
• Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes

  2020cites this paper
• EVI1 induces autophagy to promote drug resistance via regulation of ATG7 expression in leukemia cells.

  2020cites this paper
• Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells

  2020cites this paper
• Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm

  2020cites this paper
• Exploring redox vulnerabilities in JAK2V617F-positive cellular models

  2020cites this paper
• N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm.

  2020cites this paper
• Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers

  2020cites this paper
• Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms

  2020cites this paper
• Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target

  2020cites this paper
• Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms

  2020influential citation
• Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era

  2020cites this paper
• TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment.

  2020cites this paper
• JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

  2020cites this paper
• The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia

  2019cites this paper
• Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.

  2019cites this paper
• CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks.

  2019cites this paper
• Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML

  2019cites this paper
• Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis

  2019cites this paper
• Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms.

  2019cites this paper
• Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy

  2019cites this paper
• Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation

  2019cites this paper
• AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells

  2019cites this paper
• Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions

  2019cites this paper
• The Rationale for Immunotherapy in Myeloproliferative Neoplasms

  2019cites this paper
• Targeted therapies for myeloproliferative neoplasms

  2019cites this paper
• Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants

  2019cites this paper
• Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms

  2019cites this paper